Tag archive for ‘Dr. Ingunn Munch Lindvig’
By pharmanewsdaily On Monday, February 15th, 2021

Targovax gets FDA fast track status for ONCOS-102 in malignant pleural mesothelioma

Targovax, a Norwegian immune-oncology company, said that its lead candidate ONCOS-102 has secured the fast track designation from the US Food and Drug Administration (FDA) for malignant pleural mesothelioma. The More...